

The Role of Treg Cells and FoxP3 Expression in the Immunity of B Thalassemia Major and B Thalassemia Trait Patients

Thesis

*Submitted for Partial Fulfillment of
Master Degree in Pediatrics*

Presented by

Heba Othman Ragab Mohammed

M.B.B.CH

Faculty of Medicine - Cairo University

Supervised by

Prof. Dr. Ahmed Al Saeed Hamed

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Prof. Dr. Amira Abd-Monem Adly

Professor of Pediatrics

Faculty of Medicine - Ain Shams University

Dr. Eman Abdel Rahman Ismail

Consultant of Clinical Pathology

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2017

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببناك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Ahmed Al Saeed Hamed**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for his kind care, continuous supervision, valuable instructions and constant help.*

*I am deeply thankful to **Prof. Dr. Amira Abd El Monem Adly**, Professor of Pediatrics, Faculty of Medicine, Ain Shams University, for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Eman Abdel Rahman Ismail**, Consultant of Clinical Pathology, Faculty of Medicine, Ain Shams University, for her kindness, supervision and great assistance throughout this work.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Heba Osman Mohamed

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Abstract	vii
Introduction	1
Aim of the Work	4
Review of Literature	
Thalassemia	5
Etiology and Classification	5
World distribution of thalassemia	7
Genetics of Thalassemia in Egyptian population	8
Beta-thalassemia major	9
Pathophysiology of β -Thalassemia	12
Clinical picture of thalassemia	14
Manifestations of renal dysfunction in thalassemia	24
Management of thalassemia major	30
Osteoporosis	34
Lifestyle and diet in beta-thalassemia	34
Laboratory findings of thalassemia	36
Imaging Studies	38
Magnetic resonance imaging for assessment of iron overload in thalassemic patients	40
Regulatory T Cells	45
Definition and characterization	47
Development	48
The environment of regulatory T cell biology	52
Identification of Treg cells	69
Naturally occurring regulatory T cells	71

List of Contents

Title	Page No.
Induced regulatory T cells.....	74
Treg -mediated suppression.....	79
Future therapeutic perspective.....	85
Patients and Methods	86
Results	94
Discussion	110
Summary	119
Conclusion.....	122
Recommendations	123
References	124
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Summary of cytokines that influence Tregs.....	56
Table (2):	Resting and activated Tregs	61
Table (3):	Comparison between β -TM patients and controls as regard demographic data.....	94
Table (4):	Clinical data of the studied β -TM patients.....	96
Table (5):	Laboratory data of the studied β -TM patients.....	97
Table (6):	Comparison between β -TM patients and control group as regards CD4 ⁺ lymphocytes and Tregs	98
Table (7):	CD4 ⁺ T lymphocytes and Tregs in relation to clinical characteristics of β -TM patients	100
Table (8):	Correlation between CD4 ⁺ lymphocytes and Tregs and clinical and laboratory parameters among β -TM patients	103
Table (9):	Multiple linear regression analysis for variables related to CD4 ⁺ T lymphocytes in patients with β -thalassemia major	108
Table (10):	Multiple linear regression analysis for variables related to Tregs in patients with β -thalassemia major	109

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Natural and inducible regulatory T cells.....	46
Figure (2):	Treg cell differentiation as an alternative agonist antigen-induced cell fate.....	51
Figure (3):	A model of tTReg cell fate specification by TCR and accessory signals	54
Figure (4):	TReg cell recirculation and transcriptional control of TReg cell function.....	59
Figure (5):	Proposed functions of regulatory T cells	67
Figure (6):	T regulatory (Treg) cells in the control of an allergic reaction	69
Figure (7):	Targets of regulatory T cells and mechanisms of suppression.	79
Figure (8):	Targeting Treg cells in tumors.....	84
Figure (9):	Flow cytometric analysis of Tregs among patients with β -thalassemia major.	93
Figure (10):	Distribution of Tanner score for pubertal staging among β -TM patients.....	95
Figure (11):	Weight SDS values among β -TM patients compared with healthy controls.	95
Figure (12):	Percentage of CD4 ⁺ T lymphocytes in patients with β -thalassemia major and controls.	99
Figure (13):	Percentage of T regulatory cells in patients with β -thalassemia major and controls.	99

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (14):	Percentage of CD4 ⁺ T lymphocytes in β -thalassemia major patients in relation to spleen status.	101
Figure (15):	Percentage of Tregs in β -thalassemia major patients in with and without pulmonary hypertension risk.	102
Figure (16):	Frequency of Tregs in β -thalassemia major patients with ferritin ≥ 2500 and <2500 $\mu\text{g/L}$	102
Figure (17):	Correlation between the percentage of CD4 ⁺ T lymphocytes and T regulatory cells (Tregs) among β -TM patients.	104
Figure (18):	Correlation between the percentage of CD4 ⁺ T lymphocytes and WBCs count among β -TM patients.	104
Figure (19):	Correlation between the percentage of CD4 ⁺ T lymphocytes and indirect bilirubin among β -TM patients.	105
Figure (20):	Correlation between the percentage of CD4 ⁺ T lymphocytes and ALT among β -TM patients.	105
Figure (21):	Correlation between the percentage of T regulatory cells and WBCs count among β -TM patients.	106
Figure (22):	Correlation the percentage of between T regulatory cells and indirect bilirubin among β -TM patients.	106
Figure (23):	Correlation between the percentage of T regulatory cells and ferritin level among β -TM patients.	107

List of Abbreviations

Abb.	Full term
<i>APCs</i>	<i>Antigen presenting cells</i>
<i>APTT</i>	<i>Activated partial thromboplastn time</i>
<i>ATRA</i>	<i>All Trans retinoic acid</i>
<i>BIM</i>	<i>BCL-2-interacting mediator of cell death</i>
<i>CD</i>	<i>Cluster differentiation</i>
<i>CMR</i>	<i>Cardiac magnetic resonance</i>
<i>CTL</i>	<i>cytotoxic T lymphocyte</i>
<i>CTLA-4</i>	<i>Cytotoxic T lymphocyte-associated antigen 4</i>
<i>DCs</i>	<i>Dendretic cells</i>
<i>DFO</i>	<i>Deferoxamine</i>
<i>EAE</i>	<i>Experimental autoimmune encephalomyelitis</i>
<i>EDTA</i>	<i>Ethylene diamine tetra-acetic acid</i>
<i>FITC</i>	<i>Fluorescein isothiocyanate</i>
<i>FOXP3</i>	<i>Forkheadboxes P3</i>
<i>FVIII</i>	<i>Factor VIII</i>
<i>GALT</i>	<i>Gut-associated lymphoid tissue</i>
<i>GFP</i>	<i>Green fluorescent protein</i>
<i>GITR</i>	<i>Glucocorticoid-induced tumor necrosis factor</i>
<i>GRAIL</i>	<i>Gene related to anergy in lymphocytes</i>
<i>HLA</i>	<i>Human leukocyte antigen</i>
<i>HLA</i>	<i>Human leukocytic antigen</i>
<i>IDDM</i>	<i>Insulin dependent diabetes</i>
<i>IFN</i>	<i>Interferon</i>
<i>Ig</i>	<i>Immunoglobulin</i>
<i>IL</i>	<i>Interleukin</i>
<i>IL1RAcP</i>	<i>IL-1 receptor accessory protein</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>IQR</i>	<i>Inter-quartile range</i>
<i>iTreg</i>	<i>Inducible regulatory T cell</i>
<i>Kip1</i>	<i>Kinase inhibitor p27</i>
<i>LAG-3</i>	<i>Lymphocyte activation gene-3</i>
<i>MAP</i>	<i>Mitogen-activated protein</i>
<i>MAP</i>	<i>Monoclonal antibody</i>
<i>MCH</i>	<i>Mean corpuscular Hb</i>
<i>MCL1</i>	<i>Myeloid leukemia cell differentiation 1</i>
<i>MCV</i>	<i>Mean corpuscular volume</i>
<i>MHC</i>	<i>Major histocompatibility complex</i>
<i>mTOR</i>	<i>Mechanistic target of rapamycin,</i>
<i>NAG</i>	<i>N-acetyl-D-glucosaminidase</i>
<i>NKT</i>	<i>Natural killer T cell</i>
<i>NTBI</i>	<i>Non-transferrin-bound iron</i>
<i>nTreg</i>	<i>Naturally occurring regulatory T cell</i>
<i>PC5</i>	<i>Phycoerythrin-Cyanine 5</i>
<i>PE</i>	<i>Phycoerythrin</i>
<i>PI3K</i>	<i>Phosphatidylinositol 3-kinase</i>
<i>PQC</i>	<i>Protein quality control</i>
<i>PSA</i>	<i>Polysaccharide A</i>
<i>pTreg</i>	<i>Peripheral induced regulatory T cell</i>
<i>RORγt</i>	<i>retinoid-related orphan receptor γt</i>
<i>SD</i>	<i>Standard deviation</i>
<i>TAA</i>	<i>tumour-associated antigen</i>
<i>TCR</i>	<i>T cell receptor</i>
<i>Teff</i>	<i>Effector T cell</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>TF</i>	<i>Tissue factor</i>
<i>TGF</i>	<i>Transforming growth factor</i>
<i>TH</i>	<i>T helper</i>
<i>TR</i>	<i>T regulatory</i>
<i>TRAIL</i>	<i>TNF-related apoptosis-inducing ligand</i>
<i>Treg</i>	<i>Regulatory T cell</i>
<i>tTreg</i>	<i>Thymus induced regulatory T cell</i>
<i>UPS</i>	<i>Ubiquitin – proteasome system</i>
<i>B-TM</i>	<i>Beta Thalassemia Major</i>
γ c	<i>Common γ chain</i>

Abstract

Background: Immunological abnormalities in thalassemia are caused by either the illness, or therapy methods. The basis of the pathogenesis of the immunodeficiency in thalassemia is iron overload and allogenic stimulation caused by multiple blood transfusions. T regulatory cells (Tregs) are a component of the immune system that constitutes a key mechanism in maintaining peripheral self-tolerance through the control of auto-reactive lymphocyte activation. **Aim:** To determine the frequency of Tregs ($CD4^+CD25^+CD127^-$) in children and adolescents with β -thalassemia major and assessed their relation to the clinical and laboratory characteristics of patients including transfusion therapy, iron overload and alloimmunization. **Methods:** Sixty β -TM patients studied focusing on transfusion history and chelation therapy. Hematological and biochemical data including markers of hemolysis and serum ferritin were assessed. Patients' records were analyzed for the presence of alloantibodies. Assessment of T regulatory cells ($CD4^+CD25^+CD127^-$) using flow cytometry. Patients were compared with 30 healthy controls. **Results:** The percentages of $CD4^+$ T lymphocytes and Tregs were significantly reduced in β -TM patients compared with the control group ($p < 0.05$). Patients with splenectomy, heart disease and PH risk had lower levels of these cells than those without. The percentage of Tregs was decreased among patients with serum ferritin ≥ 2500 $\mu\text{g/L}$ compared with patients below this cutoff and in patients with history of alloimmune antibodies. There were significant negative correlations between Tregs and each of total and indirect bilirubin and ferritin levels while they were positively correlated with WBCs counts and hemoglobin. Multivariable linear regression analysis showed that WBCs count, hemoglobin and serum ferritin are the significant independent variables related to Tregs in patients with β -TM. **Conclusion:** Children and adolescents with β -TM may encounter a state of immune dysfunction. Low frequency of Tregs in β -TM patients may contribute to the formation of alloantibodies. Alterations in Tregs are more evident in relation to iron overload and in patients with cardiovascular complications which may reflect involvement of Tregs in disease severity. It is important to assess the suppressive activity of these cells in standard proliferation assays to examine whether their function is disrupted in β -TM together with the alteration in their frequency or not.

INTRODUCTION

β -thalassemias are heterogeneous autosomal recessive hereditary anemias characterized by reduced or absent β -globin chain synthesis. Approximately 68,000 children are born with various thalassemia syndromes each year (*Modell and Darlison, 2008; Origa et al., 2016*).

Thalassemia was first clinically described nearly a century ago and treatment of this widespread genetic disease has greatly advanced during this period. Recently, there has been a rejuvenated interest in studying thalassemia at the basic science level, leading to the discovery of previously unknown mechanisms leading to anemia and enabling the development of novel therapies (*Rund, 2016*).

Patients with β -thalassemia major (β -TM) require regular transfusions of red blood cells to survive (*Rachmilewitz and Giardina, 2011*). However, repeated transfusions cause iron overload, with life-threatening complications, such as endocrine dysfunction, cardiomyopathy, liver disease and, ultimately, premature death (*de Dreuzy et al., 2016*).

β -TM have an increased risk for serious infections, due to that a basic defect in the host defense and this may be related to the iron overload, chronic immune-stimulation by repeated blood transfusions, splenectomy and immune deficiency. Changing in lymphocyte subsets include a greater number and activity of suppressor T cells (CD-8), reduced proliferative

capacity and a number and level of activity of helper T- Cells (CD-4) leading to decreased CD4/CD8 ratio, as well as defective activity of natural killer (NK) cells. High immune globulins were reported and B-lymphocytes were found to be increased, activated with impaired differentiation, impairment of immunoglobulin secretion accompanied by increased levels of IgG, IgM and IgA. Neutrophils and macrophages are associated with defective chemo taxis and phagocytosis (*Javad et al., 2011*).

Immunological abnormalities in thalassemia are caused by either the illness, or therapy methods. The basis of the pathogenesis of the immunodeficiency in thalassemia is iron overload and allogenic stimulation caused by multiple blood transfusions. There are not numerous data about efficiency of the immunocorrection therapies for thalassmia patients (*Asadov, 2014*).

A major complication of transfusion therapy is alloimmunization, which may result in life-threatening delayed hemolytic transfusion reactions in addition to difficulties in obtaining compatible blood for transfusion (*Bauer et al., 2007*).

T regulatory cells (Tregs) are a component of the immune system that constitutes a key mechanism in maintaining peripheral self-tolerance through the control of autoreactive lymphocyte activation and the prevention of harmful effects of such activation. These cells are involved in shutting down immune responses after they have successfully eliminated invading organisms (*Caramalho et al., 2015*).

The different populations of Tregs share a common characteristic of immunosuppressive capability, but differ in their cell surface markers, types, and site of formation. Among these populations, natural Tregs, characterized by the expression of CD4⁺CD25⁺ and the transcription factor (Foxp3) (*Sakaguchi et al., 1995*), have been well studied and accumulating evidence suggests that this population plays a crucial role in the maintenance of immunological self-tolerance and negative control of pathological as well as physiological immune responses (*Fehervari and Sakaguchi, 2004*).

At present, Foxp3 is the most specific molecular marker for thymic or peripheral Tregs in rodents and humans (*Valencia and Lipsky, 2007*). It is believed that CD127 expression is down-modulated on the Treg cells and that FoxP3 interacts with the CD127 promoter and contributes to reduced expression of CD127 in Tregs (*Liu et al, 2006*). Recently, the frequency of Tregs (CD4⁺CD25⁺CD127⁻) has been found to be decreased in children with hemophilia A with inhibitor formation (*El-Asrar et al., 2016*).

Literature is limited about the role of Tregs in chronically transfused patients. Alterations in immunoregulatory T cell subsets of regularly transfused SCD patients with alloantibodies has been reported compared to those without, specifically a reduction in Treg activity, an increase toward Th2 responses and lower serum levels of IL-10 in the alloimmunized cohort (*Bao et al., 2011*).